We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

AVI BioPharma and NMRC Successfully Complete Simultaneous Rapid-Response Exercises Against Bacterial and Viral Threats in 18 Days

News   Jun 20, 2011

 
AVI BioPharma and NMRC Successfully Complete Simultaneous Rapid-Response Exercises Against Bacterial and Viral Threats in 18 Days
 
 
 

RELATED ARTICLES

Why Are Some People More Receptive to Vaccination?

News

Fear, trust, and the likelihood of exposure are three leading factors that influence whether people are willing to be vaccinated against a virulent disease, according to a new study.

READ MORE

HIV Vaccine Is a Step Closer to Clinical Trials

News

A promising vaccine that clears an HIV-like virus from monkeys is a step closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.

READ MORE

Vaccine Strategy Boosts T-Cell Therapy

News

In a study of mice, the researchers found that they could completely eliminate solid tumors in 60 percent of the animals that were given T-cell therapy along with the booster vaccination. Engineered T cells on their own had almost no effect.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE